CORDA Investment Management LLC. decreased its position in Sanofi (NASDAQ:SNY) by 0.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 129,568 shares of the company’s stock after selling 400 shares during the period. CORDA Investment Management LLC.’s holdings in Sanofi were worth $6,823,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Knowledge Leaders Capital LLC boosted its holdings in shares of Sanofi by 1.2% in the second quarter. Knowledge Leaders Capital LLC now owns 16,434 shares of the company’s stock valued at $865,000 after purchasing an additional 198 shares during the period. Ingalls & Snyder LLC lifted its holdings in Sanofi by 2.2% during the second quarter. Ingalls & Snyder LLC now owns 9,345 shares of the company’s stock worth $492,000 after buying an additional 200 shares during the period. Raymond James Trust N.A. lifted its holdings in Sanofi by 1.1% during the second quarter. Raymond James Trust N.A. now owns 18,691 shares of the company’s stock worth $984,000 after buying an additional 203 shares during the period. Clarius Group LLC lifted its holdings in Sanofi by 3.7% during the second quarter. Clarius Group LLC now owns 5,948 shares of the company’s stock worth $313,000 after buying an additional 211 shares during the period. Finally, Meridian Wealth Partners LLC lifted its holdings in Sanofi by 46.6% during the first quarter. Meridian Wealth Partners LLC now owns 777 shares of the company’s stock worth $39,000 after buying an additional 247 shares during the period. Hedge funds and other institutional investors own 8.02% of the company’s stock.
SNY stock traded down $0.28 during mid-day trading on Monday, reaching $48.10. The company’s stock had a trading volume of 36,553 shares, compared to its average volume of 2,001,705. The stock has a market cap of $121.29 billion, a PE ratio of 17.44, a P/E/G ratio of 1.38 and a beta of 0.56. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.28. Sanofi has a fifty-two week low of $44.76 and a fifty-two week high of $54.26. The company’s 50 day moving average is $51.24 and its two-hundred day moving average is $51.30.
In related news, major shareholder Sanofi bought 66,667 shares of the company’s stock in a transaction that occurred on Monday, August 2nd. The stock was purchased at an average price of $15.00 per share, for a total transaction of $1,000,005.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.00% of the stock is owned by company insiders.
A number of brokerages have recently issued reports on SNY. Morgan Stanley reaffirmed an “overweight” rating on shares of Sanofi in a research report on Friday, August 6th. UBS Group reaffirmed a “buy” rating on shares of Sanofi in a research report on Thursday, August 12th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of Sanofi in a research note on Friday, July 30th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $53.00.
Sanofi Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.
See Also: Strangles
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.